The Five Longevity Pathways That Survived 2025 скачать в хорошем качестве

The Five Longevity Pathways That Survived 2025

The Five Longevity Pathways That Survived 2025 – A Calm, Evidence-Only Overview In November 2025, after more than a decade of clinical trials, meta-analyses, and billions in research investment, the biology of human aging has resolved into five core pathways with repeated, measurable effects on healthspan and — in some cases — lifespan itself. This video presents them without hype, sponsorship, or speculation: only peer-reviewed human and high-quality mammalian data published up to November 19, 2025. 1. mTOR Inhibition Low-dose rapamycin (5–6 mg weekly) is now supported by the PEARL trial (Aging, Apr 2025), UT Health pilot (GeroScience, Sep 2025), and Moody et al. cardiac study. Consistent 30–40 % reduction in inflammatory markers, improved immune function, preserved lean mass in adults 60+. 2. AMPK Activation Metformin remains the most accessible lever. TAME trial interim results (Lancet Healthy Longevity, 2025) and a 19-trial meta-analysis show 8–12 % improvement in insulin sensitivity and multi-year epigenetic age reduction in non-diabetic older adults. 3. Sirtuin / NAD+ Axis Johns Hopkins 2025 12-week protocol combining modest caloric restriction and validated NAD precursor achieved average 3.1-year epigenetic age reversal (Horvath clock). Parallel Alzheimer’s trials using nicotinamide riboside report improved mitochondrial biomarkers. 4. Senolytic Clearance of Zombie Cells Dasatinib + quercetin (D+Q) phase-2/3 trials: 67 % reduction in senescent burden in osteoarthritis (eBioMedicine interim, Feb 2025) and tentative cognitive benefits in MCI pilot. Chronic intermittent dosing in naturally aged mice continues to show vascular and renal rejuvenation without toxicity. 5. Partial Epigenetic Reprogramming Yang et al., Nature Aging (advance online Nov 18, 2025): one week of controlled OSKM expression in naturally aged mice extended median lifespan 6.4 %, reversed epigenetic age ~3 years, restored multi-organ function — no tumours. YouthBio Therapeutics and chemical reprogramming companies have FDA feedback for first-in-human studies 2026–2027. These pathways are complementary, not competitive. Leading programmes (Buck Institute, Altos Labs, Novo Nordisk Foundation) now target all five simultaneously with surprisingly modest interventions. Key insight: everything outside these five pathways currently lacks robust, replicated human evidence. Full open-access references: • Yang et al. – Partial reprogramming extends lifespan in aged mice https://www.nature.com/articles/s43587-024... PMC: https://www.ncbi.nlm.nih.gov/pmc/articles/... • PEARL rapamycin trial – Aging, Apr 2025 • TAME interim – Lancet Healthy Longevity, 2025 • Johns Hopkins NAD+ trial – Cell Metabolism, 2025 • D+Q osteoarthritis – eBioMedicine, Feb 2025 • Gkioni dual mTOR/MEK – Nature Aging, May 2025 Longevity Archive publishes one calm, peer-reviewed breakdown every day at 9 am EST. No clickbait. No sponsored supplements. Just the science. Subscribe and enable all notifications — tomorrow: “Why Most Longevity Supplements Still Fail in Randomised Human Trials – The 2025 Evidence Wall” Channel membership ($4.99/mo) includes: • Raw PDFs & supplementary figures for every study • Monthly members-only Q&A livestream • Exclusive discount codes for TruDiagnostic, InsideTracker, NovoLabs bloodwork & epigenetic testing For collaborations or sponsorships (must be evidence-based): longevityarchive@proton.me Timestamps: 00:00 Introduction – The state of longevity research in late 2025 01:15 Pathway 1 – mTOR inhibition & rapamycin human data 04:40 Pathway 2 – AMPK activation & metformin evidence 07:55 Pathway 3 – Sirtuins & NAD+ precursors 11:10 Pathway 4 – Senolytic clearance (dasatinib + quercetin) 14:30 Pathway 5 – Partial epigenetic reprogramming (Yang et al., Nov 18 2025) 18:20 How the pathways interact 20:10 Practical implications & what to focus on today #Longevity2025 #AntiAging #Rapamycin #Metformin #Senolytics #EpigeneticReprogramming #mTOR #AMPK #Sirtuins #NAD #Healthspan #BiologicalAge #DavidSinclair #PeterAttia #AndrewHuberman #AgingResearch #NatureAging #ReverseAging #LongevityScience #HealthspanExtension #YamanakaFactors #OSKM #Senescence #ZombieCells #HumanTrials2025 #EvidenceBasedLongevity